Drug intelligence / Profile preview

methylprednisolone + theophylline

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Methylprednisolone + theophylline is a combination medication used to treat respiratory conditions. Methylprednisolone is a corticosteroid that reduces inflammation and suppresses immune responses, while theophylline acts as a bronchodilator by relaxing smooth muscle in the airways. Studies have shown that when used together, these medications have synergistic effects on diaphragm muscle contraction strength and duration. The combination is primarily used for treating asthma, chronic bronchitis, emphysema, and other chronic lung diseases.

Targets

ADOR (Adenosine receptors)PDE (Phosphodiesterase family)GR (Glucocorticoid receptor)HDAC2 (Histone deacetylase 2)

Beyond the preview

Go deeper on methylprednisolone + theophylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylprednisolone + theophylline.

Explore the full profile